NASDAQ$VERU
Veru Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Net revenues and gross profit increased, setting new quarterly records.
Veru Inc. reported a significant increase in net revenues and gross profit for the third quarter of fiscal year 2021. Net revenues increased by 71% to $17.7 million, and gross profit increased by 113% to $13.9 million. The company is focused on advancing its late-stage drug pipeline for oncology and COVID-19.
- Net revenues increased 71% to $17.7 million.
- Gross profit rose 113% to $13.9 million.
- FC2 prescription net revenues climbed 150% to $13.5 million.
- Initiated Phase 3 VERACITY clinical trial for metastatic castration resistant prostate cancer and Phase 2 VERU-100 clinical trial for advanced prostate cancer.
Headline financials
Revenue & EPS history
Veru · Revenue · Quarterly
$17.7M
Forward guidance
Veru anticipates starting Phase 3 ARTEST clinical trial of enobosarm monotherapy, Phase 2b clinical trial of enobosarm in combination with abemaciclib, and Phase 2b clinical trial for metastatic triple negative breast cancer in the second half of the calendar year.
Tailwinds
- Phase 3 ARTEST clinical trial of enobosarm monotherapy in a 3rd line metastatic setting in AR+ ER+ HER2- metastatic breast cancer.
- Phase 2b clinical trial of enobosarm in combination with abemaciclib, CDK 4/6 inhibitor, in a 2nd line metastatic setting in AR+ ER+ HER2- metastatic breast cancer.
- Phase 2b clinical trial evaluating sabizabulin monotherapy and sabizabulin + Trodelvy® (sacituzumab govitecan-hziy) combination therapy versus Trodelvy® monotherapy in metastatic triple negative breast cancer.
- PDUFA date for TADFIN for the treatment of Benign Prostatic Hyperplasia is on track for December 2021.
- Initiated Phase 3 VERACITY clinical trial for metastatic castration resistant prostate cancer.
Headwinds
- COVID-19 remains a severe threat with few effective therapies to complement the COVID-19 vaccination strategy.
- Almost all patients will develop resistance to CDK 4/6 inhibitors.
- The development of the Company’s product portfolio and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development.
- The ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules.
- The possibility that as vaccines become widely distributed the need for new COVID-19 treatment candidates may be reduced or eliminated.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
+1.5%
Avg return
Earnings day
+8.3%
Avg return
5 days after
+9.6%
Avg return
30 days after
45%
30 / 66 earnings
Positive
+83.7%
Q4 2020
Best reaction
-23.5%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.8% | -6.7% | +33.8% | |
| Q1 2026 | -0.4% | -0.9% | +3.5% | |
| Q4 2025 | -8.4% | -6.1% | +10.2% | |
| Q3 2025 | -12.0% | +0.0% | -0.8% | |
| Q2 2025 | +4.1% | +4.0% | +24.0% | |
| Q1 2025 | -4.5% | +0.0% | -12.7% | |
| Q4 2024 | -1.3% | -9.7% | +2.8% | |
| Q3 2024 | +7.1% | +6.5% | +10.4% | |
| Q4 2023 | +3.5% | +11.8% | -4.7% | |
| Q2 2024 | -16.0% | -18.4% | -43.6% | |
| Q1 2024 | -13.7% | -13.6% | +47.7% | |
| Q3 2023 | +5.6% | +3.7% | -4.6% | |
| Q2 2023 | -23.5% | -27.5% | -12.1% | |
| Q1 2023 | -19.1% | -21.8% | -57.5% | |
| Q4 2022 | +2.9% | -0.5% | -1.3% | |
| Q3 2022 | +62.1% | +89.0% | +32.3% | |
| Q2 2022 | +59.3% | +91.2% | +60.8% | |
| Q1 2022 | +9.4% | +7.4% | -8.8% | |
| Q4 2021 | -12.3% | -8.1% | -14.8% | |
| Q3 2021 | +8.8% | -2.0% | +31.3% | |
| Q2 2021 | -3.2% | +3.7% | +18.7% | |
| Q1 2021 | -2.3% | +7.8% | -22.3% | |
| Q4 2020 | +83.7% | +198.5% | +193.8% | |
| Q3 2020 | -11.6% | -10.9% | -9.9% | |
| Q2 2020 | +13.9% | +10.5% | -5.4% | |
| Q1 2020 | +0.9% | -0.9% | -29.8% | |
| Q4 2019 | -1.6% | +17.1% | +64.5% | |
| Q3 2019 | -14.0% | -11.0% | -16.2% | |
| Q2 2019 | -4.8% | -1.8% | +20.8% | |
| Q1 2019 | -8.1% | -10.7% | +0.0% | |
| Q4 2018 | -4.9% | +0.7% | -1.4% | |
| Q3 2018 | +1.0% | +1.0% | -13.6% | |
| Q2 2018 | -1.2% | +6.6% | +18.7% | |
| Q1 2018 | +0.8% | +2.3% | +50.4% | |
| Q4 2017 | +28.9% | +29.8% | +10.5% | |
| Q3 2017 | -11.3% | -4.0% | +2.0% | |
| Q2 2017 | -1.0% | -2.9% | +17.6% | |
| Q1 2017 | +1.9% | +3.8% | -1.9% | |
| Q4 2016 | -6.2% | -8.8% | -10.6% | |
| Q3 2016 | -2.3% | +1.6% | +2.3% | |
| Q2 2016 | -12.3% | — | — | |
| Q1 2016 | +10.2% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +9.9% | — | — | |
| Q2 2015 | -8.1% | — | — | |
| Q1 2015 | +2.9% | — | — | |
| Q4 2014 | -8.5% | — | — | |
| Q3 2014 | -5.8% | — | — | |
| Q2 2014 | -3.7% | — | — | |
| Q1 2014 | -4.1% | — | — | |
| Q4 2013 | +3.4% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q2 2013 | +5.8% | — | — | |
| Q1 2013 | -4.2% | — | — | |
| Q4 2012 | -0.7% | — | — | |
| Q3 2012 | +4.7% | — | — | |
| Q2 2012 | -9.2% | — | — | |
| Q1 2011 | +1.5% | — | — | |
| Q1 2012 | +4.7% | — | — | |
| Q4 2009 | +5.5% | — | — | |
| Q4 2011 | +5.5% | — | — | |
| Q2 2011 | +5.5% | — | — | |
| Q4 2010 | -5.4% | — | — | |
| Q3 2010 | -5.4% | — | — | |
| Q3 2011 | -5.4% | — | — | |
| Q2 2010 | +0.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro